BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 8750621)

  • 1. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
    Martyré MC
    Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.
    Le Bousse-Kerdilès MC; Martyré MC;
    Pathol Biol (Paris); 2001 Mar; 49(2):153-7. PubMed ID: 11317961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
    Le Bousse-Kerdilès MC; Martyré MC
    Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Megakaryocytes and platelets in myeloproliferative disorders.
    Briere J; Kiladjian JJ; Peynaud-Debayle E
    Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspective in agnogenic myeloid metaplasia.
    Tefferi A; Silverstein MN
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():169-71. PubMed ID: 8951788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet PDGF and TGF-β Levels in Myeloproliferative Disorders.
    Martyré MC
    Leuk Lymphoma; 1991; 6(1):1-6. PubMed ID: 27457569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cells (third of three parts).
    Quesenberry P; Levitt L
    N Engl J Med; 1979 Oct; 301(16):868-72. PubMed ID: 384249
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histopathology of Ph1-negative chronic myeloproliferative diseases].
    Georgii A; Choritz H; Büsche G; Kreft A; Buhr T
    Pathologe; 1995 Jan; 16(1):62-9. PubMed ID: 7886016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spectrum of myeloproliferative disorders.
    Gilbert HS
    Med Clin North Am; 1973 Mar; 57(2):355-93. PubMed ID: 4570933
    [No Abstract]   [Full Text] [Related]  

  • 13. The pathogenesis of spleen mediated phenomena in chronic myeloid leukaemia and agnogenic myeloid metaplasia: a non-abscopal mechanism.
    Adler SS
    Scand J Haematol; 1976 Sep; 17(3):153-9. PubMed ID: 788139
    [No Abstract]   [Full Text] [Related]  

  • 14. Clonal analysis of agnogenic myeloid metaplasia.
    Kreipe H; Jaquet K; Felgner J; Parwaresch MR
    Leuk Lymphoma; 1992 Dec; 8(6):459-64. PubMed ID: 1363649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis.
    Martyré MC; Le Bousse-Kerdiles MC; Romquin N; Chevillard S; Praloran V; Demory JL; Dupriez B
    Br J Haematol; 1997 May; 97(2):441-8. PubMed ID: 9163611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models.
    Chagraoui H; Wendling F; Vainchenker W
    Best Pract Res Clin Haematol; 2006; 19(3):399-412. PubMed ID: 16781480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 18. Abnormal myelopoietic clones in man.
    McCulloch EA
    J Natl Cancer Inst; 1979 Oct; 63(4):883-92. PubMed ID: 384008
    [No Abstract]   [Full Text] [Related]  

  • 19. Stem cell origin of human myeloid blood cell neoplasms.
    Fialkow PJ
    Verh Dtsch Ges Pathol; 1990; 74():43-7. PubMed ID: 1708632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.